• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Motixafortide Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5754621

MBS5754621 is an inhibitor targeting Motixafortide. Motixafortide (BKT140 4-fluorobenzoyl) is an antagonist of CXCR4 (IC50: 1nM). More details

Please Inquire
Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Motixafortide, Inhibitor
Full Product Name
Motixafortide
Product Synonym Names
BKT140 (4-fluorobenzoyl); BL-8040; TF14016
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
2159.52
Solubility
DMSO: 36mg/mL (16.67mM)
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C97H144FN33O19S2
SMILES
[4F-Benzoyl-RR-{2-Naph-Ala}-CY-{Cit}-KKPYR-{Cit}-CR-NH2 (Disulfide bridge: Cys4-Cys13)]
CAS Number
664334-36-5
Target & IC50
CXCR4: ic50 1nM
In Vitro
Tumors from animals treated with Motixafortide (BKT140) are smaller in size and weights, had larger necrotic areas and high apoptotic scores[2]. Subcutaneous injections of Motixafortide (BKT140) significantly reduces, in a dose-dependent manner, the growth of human acute myeloid leukemia and multiple myeloma xenografts.

Product Categories/Family for Motixafortide, inhibitor

Autophagy; CXCR; GPCR/G Protein; Immunology/Inflammation

Product References and Citations for Motixafortide, inhibitor

Peled A, et al. The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cellsin patients with multiple myeloma. Clin Cancer Res. 2014 Jan 15;20(2):469-79.
Peled A, et al. The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cellsin patients with multiple myeloma. Clin Cancer Res. 2014 Jan 15;20(2):469-79.
Beider K, et al. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp Hematol. 2011 Mar;39(3):282-92.
Beider K, et al. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp Hematol. 2011 Mar;39(3):282-92.

Other Notes

Small volumes of Motixafortide, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000